The pharmacy, called NovoCare, will allow patients to pay $499 in cash per month for the blockbuster weight loss drug.

Novo Nordisk A/S's CagriSema faces challenges, yet new trials aim to enhance efficacy, rival Eli Lilly in obesity treatments, ...

Accordingly, shareholders can choose between participating in person at Bella Center, Center Boulevard 5, DK-2300 Copenhagen ...

Novo Nordisk A/S (NYSE: NVO) has declared that its GLP-1 drugs for chronic obesity, under the brands Ozempic and Wegovy, are ...

As part of its ongoing efforts to ensure patients who need Wegovy, or semaglutide, injection 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, and 2.4 mg can ...

Novo Nordisk (NVO) warns U.S. tariffs on pharmaceuticals may lead to drug shortages & price hikes. Read more here.

Novo Nordisk A/S (NVO) has slashed prices for its blockbuster weight-loss drug Wegovy as competition in the obesity drug market heats up, with ...

Bagsværd, Denmark, 27 February 2025 - The Annual General Meeting of Novo Nordisk A/S will be held on: Thursday 27 March 2024 at 14.00 (CET) The Annual General Meeting is held as a partially ...

Still, Novo is steadfast in its goal to eventually become a leader in the space, the company’s EVP of rare disease, Ludovic ...

Investing.com -- Shares of Novo Nordisk (NYSE: NVO) tumbled 6% today, following the announcement of results from its REDEFINE 2 phase 3 trial. Despite meeting its primary endpoint, showing ...

Novo Nordisk NVO announced that it is launching a new direct-to-patient online pharmacy called NovoCare, which will offer its ...